BioMotiv, Cure Network developing inhibitory interneuron small molecules

BioMotiv LLC (Cleveland, Ohio) partnered with Cure Network Dolby Acceleration Partners LLC (CNDAP) to develop small molecules that improve the function of inhibitor interneurons to treat neurological disorders, including Dravet syndrome, other epilepsies and Alzheimer’s disease. Financial terms were not disclosed.

The collaboration will focus on research from the lab of Jorge Palop, which has shown that enhancing inhibitor interneuron function by overexpressing sodium voltage-gated channel alpha subunit 1 (Nav1.1; SCN1A) improved cognitive function in a mouse model of AD. Palop is a researcher at the Gladstone Institutes...